Jpmorgan Chase & CO Mirati Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$41.99 - $62.38 $1.62 Million - $2.4 Million	38,528 Added 55.14%	108,407 $6.37 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $856,379 - $1.4 Million	30,805 Added 78.84%	69,879 $3.04 Million
Q2 2023 Aug 11, 2023	SELL	$36.13 - $49.49 $750,564 - $1.03 Million	-20,774 Reduced 34.71%	39,074 $1.41 Million
Q1 2023 May 18, 2023	BUY	$36.54 - $54.26 $1.06 Million - $1.57 Million	28,980 Added 93.88%	59,848 $2.23 Million
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $443,522 - $658,607	-12,138 Reduced 28.22%	30,868 $1.15 Million
Q4 2022 Feb 13, 2023	SELL	$41.27 - $98.62 $4.82 Million - $11.5 Million	-116,870 Reduced 73.1%	43,006 $1.95 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $6.26 Million - $9.12 Million	105,147 Added 192.12%	159,876 $11.2 Million
Q2 2022 Aug 11, 2022	BUY	$39.16 - $88.71 $1.04 Million - $2.35 Million	26,463 Added 93.62%	54,729 $3.67 Million
Q1 2022 May 11, 2022	BUY	$75.82 - $150.97 $164,074 - $326,699	2,164 Added 8.29%	28,266 $2.32 Million
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $430,220 - $620,155	3,259 Added 14.27%	26,102 $3.83 Million
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $3.02 Million - $4.05 Million	22,843 New	22,843 $4.04 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.